EA033343B1 - Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой - Google Patents

Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой

Info

Publication number
EA033343B1
EA033343B1 EA201792047A EA201792047A EA033343B1 EA 033343 B1 EA033343 B1 EA 033343B1 EA 201792047 A EA201792047 A EA 201792047A EA 201792047 A EA201792047 A EA 201792047A EA 033343 B1 EA033343 B1 EA 033343B1
Authority
EA
Eurasian Patent Office
Prior art keywords
rip2 kinase
treatment
pharmaceutical composition
kinase
composition based
Prior art date
Application number
EA201792047A
Other languages
English (en)
Other versions
EA201792047A1 (ru
Inventor
Линда Н. Касиллас
Джон Дэвид Харлинг
Афджал Хуссайн Миах
Марк Дэвид Рэкхэм
Иан Эдвард Дэвид Смит
Original Assignee
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед filed Critical Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Publication of EA201792047A1 publication Critical patent/EA201792047A1/ru
Publication of EA033343B1 publication Critical patent/EA033343B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к соединениям, композициям и лекарственным средствам, содержащим указанные соединения. Изобретение также относится к применению указанных соединений, композиций и лекарственных средств, например, в качестве ингибиторов активности RIP2-киназы (взаимодействующая с рецептором протеинкиназа 2), в том числе осуществляющих деградацию RIP2-киназы, для лечения заболеваний и состояний, опосредуемых RIP2-киназой, в частности, для лечения воспалительных заболеваний или состояний.
EA201792047A 2015-04-22 2016-04-20 Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой EA033343B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506872.9A GB201506872D0 (en) 2015-04-22 2015-04-22 Novel compounds
PCT/US2016/028332 WO2016172134A2 (en) 2015-04-22 2016-04-20 Novel compounds

Publications (2)

Publication Number Publication Date
EA201792047A1 EA201792047A1 (ru) 2018-04-30
EA033343B1 true EA033343B1 (ru) 2019-09-30

Family

ID=53299021

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792047A EA033343B1 (ru) 2015-04-22 2016-04-20 Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой

Country Status (21)

Country Link
US (2) US10435391B2 (ru)
EP (1) EP3286169B1 (ru)
JP (1) JP2018513867A (ru)
KR (1) KR20170139096A (ru)
CN (1) CN107709305B (ru)
AU (1) AU2016252404B2 (ru)
BR (1) BR112017022604A2 (ru)
CA (1) CA2983414A1 (ru)
CL (1) CL2017002650A1 (ru)
CO (1) CO2017011851A2 (ru)
CR (1) CR20170478A (ru)
EA (1) EA033343B1 (ru)
ES (1) ES2841548T3 (ru)
GB (1) GB201506872D0 (ru)
HK (1) HK1243410A1 (ru)
IL (1) IL255067A0 (ru)
MX (1) MX2017013556A (ru)
PE (1) PE20180044A1 (ru)
PH (1) PH12017501921A1 (ru)
SG (1) SG11201708311UA (ru)
WO (1) WO2016172134A2 (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
US10071164B2 (en) * 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR20220029783A (ko) 2015-01-20 2022-03-08 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
MX2017011919A (es) 2015-03-18 2018-05-22 Arvinas Inc Compuestos y metodos para la degradacion mejorada de proteinas especificas.
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
EP3302482A4 (en) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CA3020792A1 (en) * 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors
CA3087528C (en) 2016-09-15 2024-01-30 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
IL304982A (en) 2016-11-01 2023-10-01 Arvinas Operations Inc PROTACS Targeted Tau-Protein and Related Methods of Use
EP3548483A4 (en) 2016-12-01 2020-06-10 Arvinas Operations, Inc. TETRAHYDRONAPHTHALINE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS AN ESTROGEN RECEPTOR-DEGRADING AGENT
KR102564201B1 (ko) 2016-12-23 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
AU2017382406A1 (en) 2016-12-23 2019-04-18 Arvinas Operations, Inc. EGFR proteolysis targeting chimeric molecules and associated methods of use
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
JP7266526B6 (ja) 2017-01-26 2024-02-15 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体タンパク質分解性の調節因子およびその関連方法
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
CN107987083A (zh) * 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物
JP2021512153A (ja) 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
AU2019249231B2 (en) 2018-04-04 2022-04-21 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
JPWO2020027225A1 (ja) 2018-07-31 2021-11-11 ファイメクス株式会社 複素環化合物
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
CN112638905A (zh) * 2018-08-28 2021-04-09 南京明德新药研发有限公司 作为rip2激酶抑制剂的喹唑啉类衍生物
CN113677668A (zh) 2019-01-30 2021-11-19 蒙特利诺治疗公司 用于雄激素受体靶向泛素化的双官能化合物和方法
US11547759B2 (en) 2019-01-30 2023-01-10 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
CA3133314A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicle conjugates and uses thereof
US20220387906A1 (en) 2019-03-21 2022-12-08 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
JP2021024787A (ja) 2019-07-31 2021-02-22 ファイメクス株式会社 複素環化合物
JPWO2021020585A1 (ru) 2019-07-31 2021-02-04
KR20220119094A (ko) 2019-12-19 2022-08-26 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
WO2022061348A1 (en) * 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022197862A1 (en) * 2021-03-17 2022-09-22 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
EP4323352A1 (en) 2021-04-16 2024-02-21 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
US11981672B2 (en) 2021-09-13 2024-05-14 Montelino Therapeutics Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
WO2023180388A1 (en) 2022-03-24 2023-09-28 Glaxosmithkline Intellectual Property Development Limited 2,4-dioxotetrahydropyrimidinyl derivatives as degrons in protacs
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
CN115869308B (zh) * 2022-12-30 2024-03-26 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种小分子化合物在制备抗结直肠癌药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128632A1 (en) * 2002-07-02 2006-06-15 Sharma Sushil K Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
US20100273812A1 (en) * 2007-04-13 2010-10-28 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
WO2014043437A1 (en) * 2012-09-13 2014-03-20 Glaxosmithkline Llc Amino-quinolines as kinase inhibitors
US20140356322A1 (en) * 2012-01-12 2014-12-04 Yale University Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773348A4 (en) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
MX2009011783A (es) 2007-04-30 2009-12-04 Genentech Inc Inhibidores de iap.
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
EP2491041B1 (en) 2009-10-23 2017-08-09 The Regents of the University of Michigan Bivalent diazo bicyclic smac mimetics and the uses thereof
JP2013526484A (ja) 2010-05-07 2013-06-24 グラクソ グループ リミテッド キナーゼ阻害剤としてのアミノ‐キノリン
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
CA2829131C (en) * 2011-03-04 2018-11-20 Glaxosmithkline Intellectual Property (No.2) Limited Amino-quinolines as kinase inhibitors
TWI547494B (zh) * 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AU2013306087B2 (en) 2012-08-23 2017-08-10 The Regents Of The University Of Michigan Bivalent inhibitors of IAP proteins and therapeutic methods using the same
TWI592417B (zh) * 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
WO2014047024A1 (en) * 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
EP2903998B1 (en) 2012-10-02 2017-03-15 Bristol-Myers Squibb Company Iap antagonists
PE20151083A1 (es) 2012-12-11 2015-08-06 Hoffmann La Roche Compuestos dimericos
CN105143208B (zh) 2013-02-21 2017-09-26 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的喹唑啉
JP6778114B2 (ja) 2014-04-14 2020-10-28 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． イミド系タンパク質分解モジュレーター及び関連する使用方法
US9346815B2 (en) 2014-05-23 2016-05-24 Genentech, Inc. 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof
RU2017111200A (ru) 2014-09-05 2018-10-05 Мерк Патент Гмбх Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака
GB201506871D0 (en) * 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
TW201642860A (zh) 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑
EP3286181B1 (en) 2015-04-22 2021-01-27 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
GB201516243D0 (en) * 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
CA3020792A1 (en) * 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128632A1 (en) * 2002-07-02 2006-06-15 Sharma Sushil K Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
US20100273812A1 (en) * 2007-04-13 2010-10-28 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
US20140356322A1 (en) * 2012-01-12 2014-12-04 Yale University Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
WO2014043437A1 (en) * 2012-09-13 2014-03-20 Glaxosmithkline Llc Amino-quinolines as kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUCKLEY et al. 'Small Molecule Control of Intracellular Protein Levels Through Modulation of the Ubiquitin Proteasome System', Angew Chem Int Ed Engl. 2014, Vol.53(9), pp 2312-2330. pg 29, Fig 6; pg 35, Fig 11 *
PENG et al. 'Bivalent Smac Mimetics with a Diazabicyclic Core as Highly Potent Antagonists of XIAP and clAP1/2 and Novel Anticancer Agents', Journal of Medicinal Chemistry, 2012, Vol.55, pages 106-114 [Published Online: December 2011]; pg 107, Fig 1; Table 1; pg 108, Fig 3 *

Also Published As

Publication number Publication date
EP3286169B1 (en) 2020-10-07
US20190382381A1 (en) 2019-12-19
MX2017013556A (es) 2018-08-01
EP3286169A2 (en) 2018-02-28
IL255067A0 (en) 2017-12-31
ES2841548T3 (es) 2021-07-08
PH12017501921A1 (en) 2018-03-19
BR112017022604A2 (pt) 2018-07-17
EP3286169A4 (en) 2018-11-21
KR20170139096A (ko) 2017-12-18
CN107709305A (zh) 2018-02-16
GB201506872D0 (en) 2015-06-03
WO2016172134A3 (en) 2016-12-01
CA2983414A1 (en) 2016-10-27
SG11201708311UA (en) 2017-11-29
HK1243410A1 (zh) 2018-07-13
JP2018513867A (ja) 2018-05-31
CR20170478A (es) 2018-01-22
US10435391B2 (en) 2019-10-08
CL2017002650A1 (es) 2018-03-16
PE20180044A1 (es) 2018-01-15
US20180134688A1 (en) 2018-05-17
CO2017011851A2 (es) 2018-02-09
EA201792047A1 (ru) 2018-04-30
CN107709305B (zh) 2020-09-29
AU2016252404A1 (en) 2017-12-07
WO2016172134A2 (en) 2016-10-27
AU2016252404B2 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
EA033343B1 (ru) Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12015501385A1 (en) Autotaxin inhibitors
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MD20150043A2 (ru) Ингибиторы гистон деметилаз
WO2013173441A3 (en) Enhancer of zeste homolog 2 inhibitors
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
NZ708593A (en) Novel pyrazole derivative
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2017014035A (es) Formas solidas novedosas.
TN2012000534A1 (en) Pyrazole compounds as sigma receptor inhibitors
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
EA033236B1 (ru) Новые производные пиразола в качестве ингибиторов nik
PH12016501462A1 (en) Neprilysin inhibitors
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MX2014003455A (es) Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide.
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
MX2021005273A (es) Inhibidores de quinasa rock.
EP3360581A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER WITH INHIBITOR OF PLRG1 (PLEIOTROPER REGULATOR 1) AS AN ACTIVE SUBSTANCE

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU